Arthur Klausner discusses liquidation and participating preferred stock in the third part of his series on VC term sheets.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.
Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.
The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.
